A051701-Randomized Phase II/III Study of Venetoclax (ABT 199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double-Expressing Lymphomas

January 05, 2020
https://clinicaltrials.gov/ct2/show/NCT03984448
Cancer - Lymphoma
Principal Investigator: Ding Wang, MD
Lymphoma, diffuse large B-cell lymphoma, high grade B-cell lymphoma, double expressing lymphoma 
Accepting Participants